Benzinga Pro data, Candel Therapeutics (NASDAQ:CADL) reported Q2 sales of $31 thousand. Earnings fell to a loss of $4.15 million, resulting in a 374.71% decrease from last quarter. In Q1, Candel Therapeutics brought in $31 thousand in sales but lost $874 thousand in earnings.

Why Is ROCE Significant?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Candel Therapeutics posted an ROCE of -0.07%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

For Candel Therapeutics, a negative ROCE ratio of -0.07% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Upcoming Earnings Estimate

Candel Therapeutics reported Q2 earnings per share at $-0.3/share, which beat analyst predictions of $-0.41/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.